Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.

Cunningham, Evan B; Hajarizadeh, Behzad; Amin, Janaki; Litwin, Alain H; Gane, Edward; Cooper, Curtis; Lacombe, Karine; Hellard, Margaret; Read, Phillip; Powis, Jeff; Dalgard, Olav; Bruneau, Julie; Matthews, Gail V; Feld, Jordan J; Dillon, John F; Shaw, David; Bruggmann, Philip; Conway, Brian; Fraser, Chris; Marks, Philippa; ... (2020). Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clinical infectious diseases, 71(7), e115-e124. Oxford University Press 10.1093/cid/ciz1089

[img] Text
ciz1089.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (9MB) | Request a copy

BACKGROUND

This study investigated adherence and associated factors among people with recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once-daily to twice-daily hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy.

METHODS

SIMPLIFY and D3FEAT are international, multicenter studies that recruited participants with recent IDU (previous 6 months; SIMPLIFY, D3FEAT) or current OAT (D3FEAT) between March 2016 and February 2017 in 8 countries. Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritaprevir/ritonavir/ombitasvir, dasabuvir (twice daily) ± ribavirin (D3FEAT) for 12 weeks administered in electronic blister packs. We evaluated overall adherence (proportion of prescribed doses taken) and nonadherence (<90% adherent) between dosing patterns.

RESULTS

Of 190 participants, 184 (97%) completed treatment. Median adherence was 92%, with higher adherence among those receiving once-daily vs twice-daily therapy (94% vs 87%, P = .005). Overall, 40% of participants (n = 76) were nonadherent (<90% adherent). Recent stimulant injecting (odds ratio [OR], 2.48 [95% confidence interval {CI}, 1.28-4.82]), unstable housing (OR, 2.18 [95% CI, 1.01-4.70]), and twice-daily dosing (OR, 2.81 [95% CI, 1.47-5.36]) were associated with nonadherence. Adherence decreased during therapy. Sustained virologic response was high in nonadherent (89%) and adherent populations (95%, P = .174), with no difference in SVR between those who did and did not miss 7 consecutive doses (92% vs 93%, P = .897).

CONCLUSIONS

This study demonstrated high adherence to once- and twice-daily DAA therapy among people with recent IDU or currently receiving OAT. Nonadherence described did not impact treatment outcomes, suggesting forgiveness to nonadherence.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

ISSN:

1537-6591

Publisher:

Oxford University Press

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

23 Nov 2020 16:35

Last Modified:

23 Nov 2020 16:43

Publisher DOI:

10.1093/cid/ciz1089

PubMed ID:

31677262

Additional Information:

SIMPLIFY and D3FEAT study groups: Christine Thurnheer, Leitende Ärztin Universitätsklinik für Infektiologie

Uncontrolled Keywords:

HCV OAT PWID injection drug users treatment

BORIS DOI:

10.7892/boris.148178

URI:

https://boris.unibe.ch/id/eprint/148178

Actions (login required)

Edit item Edit item
Provide Feedback